Innovative drug research and development company Shenzhen TargetRx recently announced that the company has raised 150 million yuan in a Series A financing round.
This round of investment was led by CCB International's Jianxing Fund, with participation from Oriental Fortune Capital, Tsing-yuan Capital, and existing investor Shenzhen Capital Group and others.
The proceeds will be mainly used for the clinical research of the company's small molecule compounds for the treatment of chronic myeloid leukemia and small molecule compounds for the treatment of non-small cell lung cancer, as well as the research and development of other new-generation targeted drugs.
Founded in August 2014, Shenzhen TargetRx is a China-American joint venture, high-tech pharmaceutical research and development company. A developer of targeted anti-cancer drugs, the company is committed to solve the problems of drug resistance in cancer treatment and develop innovative drugs for more effective cancer treatment.